Expertise in
16
conditions

Dr. Joel Picus

Oncology
Washington University School Of Medicine
4921 Parkview Pl, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
16
conditions
Washington University School Of Medicine
4921 Parkview Pl, 
Saint Louis, MO 

Overview

Joel Picus is an Oncologist practicing medicine in Saint Louis, Missouri.

Dr. Picus is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, and Orchiectomy.

He is actively involved in clinical research, co-authoring 58 peer reviewed articles and participating in 31 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in MO

Hospital Affiliations

Barnes-Jewish West County Hospital
Barnes Jewish Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Washington University School of Medicine
4921 Parkview Pl, Saint Louis, MO 63110
Other Locations
Office
4921 Parkview Pl Fl 7, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase I/II Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Phase I/II Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Enrollment Status: Recruiting
Publish Date: February 11, 2026
Intervention Type: Radiation, Drug
Study Phase: Phase 1/Phase 2
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 16, 2026
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Enrollment Status: Active_not_recruiting
Publish Date: June 01, 2026
Intervention Type: Drug
Study Drugs: Olaparib, Abiraterone acetate, Prednisone
Study Phase: Phase 2
A Pilot Study Combining Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
A Pilot Study Combining Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 1
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
Enrollment Status: Terminated
Publish Date: March 03, 2026
Intervention Type: Drug
Study Drugs: DFF332, RAD001, PDR001, NIR178
Study Phase: Phase 1
View 8 Less Clinical Trials

58 Total Publications

Exploratory FDG PET/CT Imaging in mCRPC Patients Treated with Sipuleucel-T ± IL-7: A Phase II Trial Subanalysis.
Exploratory FDG PET/CT Imaging in mCRPC Patients Treated with Sipuleucel-T ± IL-7: A Phase II Trial Subanalysis.
Journal: International journal of molecular sciences
Published: March 17, 2026
Similar Doctors
Expertise in
34
conditions
Expertise in
34
conditions
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.2 miles away)
314-362-7578
Languages Spoken:
English
See accepted insurances

Nancy Bartlett is an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Bartlett is highly rated in 34 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.2 miles away)
314-362-7578
Languages Spoken:
English
See accepted insurances

Ramaswamy Govindan is an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Govindan is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Washington University

660 S Euclid Ave, 
Saint Louis, MO 
 (0.1 miles away)
314-362-3181
Languages Spoken:
English
See accepted insurances

David Mutch is an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Mutch is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Vulvar Cancer, Hysterectomy, and Tubal Ligation.

Frequently Asked Questions about Dr. Joel Picus

How do I make an appointment with Dr. Joel Picus?

You can book an appointment with Dr. Joel Picus by calling their office at 314-362-7578. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joel Picus a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joel Picus is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joel Picus specialize in?

While Dr. Joel Picus is a Oncology, they have specific expertise in Prostate Cancer, Renal Cell Carcinoma (RCC), and Clear Cell Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Joel Picus participate in research or clinical trials?

Yes. Dr. Joel Picus has published 58 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Joel Picus's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joel Picus accept my insurance?

Dr. Joel Picus accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-362-7578 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Picus's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 58 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile